Cargando…

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease

Empagliflozin is a novel type of sodium-glucose cotransporter two inhibitor with diverse beneficial effects in the treatment of nonalcoholic fatty liver disease (NAFLD). Although empagliflozin impacts NAFLD by regulating lipid metabolism, the underlying mechanism has not been fully elucidated. In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuting, Kan, Chengxia, Qiu, Hongyan, Liu, Yongping, Hou, Ningning, Han, Fang, Shi, Junfeng, Sun, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724565/ https://www.ncbi.nlm.nih.gov/pubmed/34992540 http://dx.doi.org/10.3389/fphar.2021.793586

Ejemplares similares

Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
por: Ma, Yuting, et al.
Publicado: (2022)

Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice
por: Shi, Junfeng, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
por: Niu, Shu, et al.
Publicado: (2023)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy
por: Zhang, Le, et al.
Publicado: (2022)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2022)

Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease
por: Yang, Keungmo, et al.
Publicado: (2023)

Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells
por: Qu, Na, et al.
Publicado: (2022)

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
por: Cui, Huantian, et al.
Publicado: (2020)

Editorial: Nonalcoholic fatty liver disease: From pathogenesis to phytomedicine based on omics technology
por: Ji, Guang, et al.
Publicado: (2022)

Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1–Adiponectin Axis
por: Ye, Tongtong, et al.
Publicado: (2022)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
por: Song, Chong, et al.
Publicado: (2023)

An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
por: Pei, Ke, et al.
Publicado: (2020)

Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Zhang, Yuyuan, et al.
Publicado: (2022)

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice
por: Sun, Qin-Juan, et al.
Publicado: (2021)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Peng, Sihan, et al.
Publicado: (2022)

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
por: Aragón-Herrera, Alana, et al.
Publicado: (2022)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Growth differentiation factor 11: a “rejuvenation factor” involved in regulation of age-related diseases?
por: Ma, Yuting, et al.
Publicado: (2021)

Protective Effects of Tiaoganquzhi Decoction in Treating inflammatory Injury of Nonalcoholic Fatty liver Disease by Promoting CGI-58 and Inhibiting Expression of NLRP3 Inflammasome
por: Zhang, Huicun, et al.
Publicado: (2022)

Protective Effects and Mechanisms of Yinchen Linggui Zhugan Decoction in HFD-Induced Nonalcoholic Fatty Liver Disease Rats Based on Network Pharmacology and Experimental Verification
por: Jiang, Hui, et al.
Publicado: (2022)

Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
por: Feng, Yanbo, et al.
Publicado: (2021)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Da-Chai-Hu Decoction Ameliorates High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Through Remodeling the Gut Microbiota and Modulating the Serum Metabolism
por: Cui, Huantian, et al.
Publicado: (2020)

Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis
por: Liang, Wenyi, et al.
Publicado: (2021)

Ilexsaponin A(1) Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice
por: Zhao, Wen-wen, et al.
Publicado: (2021)

Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization
por: Li, Shuxuan, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants
por: Zhang, Wenji, et al.
Publicado: (2022)

Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
por: Su, Changtian, et al.
Publicado: (2022)

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease
por: Pastore, Mirella, et al.
Publicado: (2019)

Network Pharmacology-Based Analysis of Pogostemon cablin (Blanco) Benth Beneficial Effects to Alleviate Nonalcoholic Fatty Liver Disease in Mice
por: Cui, Yizhe, et al.
Publicado: (2021)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
por: Fon Tacer, Klementina, et al.
Publicado: (2011)

Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
por: Hall, Zoe, et al.
Publicado: (2017)

Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
por: Bhat, Neha, et al.
Publicado: (2023)

Effect of theaflavin-3,3′-digallate on leptin-deficient induced nonalcoholic fatty liver disease might be related to lipid metabolism regulated by the Fads1/PPARδ/Fabp4 axis and gut microbiota
por: Zhou, Cheng, et al.
Publicado: (2022)

FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism
por: Zhao, Fanrong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a4b52ce2j1h3tfjcqv1minpsj5